In September 2014, Allegro Diagnostics, Inc. was acquired by molecular cytology firmVeracyte, Inc. (Nasdaq: VCYT) (formerly doing business as Calderome, Inc). With a focus on developing diagnostics for thyroid and non-small cell lung cancer. Allegro Diagnostics, Inc. is also a molecular diagnostics company who test under development were judged as having the potential to enable the early diagnosis, staging and informed treatment of lung cancer and other lung diseases. The company has developed a molecular testing platform that is based on the discovery of a genomic biomarker for lung cancer. This platform has generated multiple product candidates that analyze specific changes in gene expression in epithelial cells of the airway, which are associated with the development in lung cancer in current or former tobacco smokers. Allegros first product candidate is BronchoGen, which can be incorporated into standard bronchoscopy procedures to provide additional critical diagnostic information to support more rapid diagnosis and treatment.
